NLRP3 and gout: Other NLRP3 inhibitors, such as OLT1177, have already undergone phase II clinical trials for acute gouty arthritis, and oridonin, the main active compound in the over‐the‐counter herb Rabdosia rubescens, has been indirectly used in clinical treatments.[28] However, the clinical application of PIN has not advanced as quickly as anticipated.